Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

Andreas Schneeweiss¹, Johannes Ettl², Diana Lüftner³, Matthias W Beckmann⁴, Erik Belleville⁵, Peter A Fasching⁶, Tanja N Fehm⁷, Matthias Geberth⁸, Lothar Häberle⁹, Peyman Hadji¹⁰, Andreas D Hartkopf¹¹, Carsten Hielscher¹², Jens Huober¹³, Eugen Ruckhäberle⁷, Wolfgang Janni¹³, Hans Christian Kolberg¹⁴, Christian M Kurbacher¹⁵, Evelyn Klein², Michael P Lux⁴, Volkmar Müller¹⁶, Naiba Nabieva⁴, Friedrich Overkamp¹⁷, Hans Tesch¹⁸, Elena Laakmann¹⁶, Florin-Andrei Taran¹¹, Julia Seitz¹⁹, Christoph Thomssen²⁰, Michael Untch²¹, Pauline Wimberger²², Rachel Wuerstlein²³, Bernhard Volz⁴, Diethelm Wallwiener¹¹, Markus Wallwiener²⁴, Sara Y Brucker¹¹

Affiliations

¹ National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany.
² Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
³ Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncolo0gy and Tumour Immunology, Berlin, Germany.
⁴ Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany.
⁵ ClinSol GmbH & Co KG, Würzburg, Germany.
⁶ Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany. Electronic address: peter.fasching@uk-erlangen.de.
⁷ Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Germany.
⁸ Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany.
⁹ Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany; Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Erlangen, Germany.
¹⁰ Frankfurt Center of Bone Health Frankfurt, Germany.
¹¹ Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.
¹² gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany.
¹³ Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
¹⁴ Marienhospital Bottrop, Bottrop, Germany.
¹⁵ Gynecology I (Gynecologic Oncology), Gynäkologisches Zentrum Bonn Friedensplatz, Bonn, Germany.
¹⁶ Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
¹⁷ Oncologianova GmbH, Recklinghausen, Germany.
¹⁸ Oncology Practice at Bethanien Hospital, Frankfurt, Germany.
¹⁹ National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
²⁰ Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
²¹ Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany.
²² National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Dresden University Hospital, Dresden, Germany.
²³ Department of Gynecology and Obstetrics, Breast Center, and CCC Munich, Munich University Hospital, Germany.
²⁴ Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.

PMID: 33413981
PMCID: PMC7878444
DOI: 10.1016/j.breast.2020.12.007

Published Erratum

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

Andreas Schneeweiss et al. Breast. 2021 Feb.

. 2021 Feb:55:138-139.

doi: 10.1016/j.breast.2020.12.007. Epub 2021 Jan 5.

Authors

Affiliations

¹ National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany.
² Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
³ Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncolo0gy and Tumour Immunology, Berlin, Germany.
⁴ Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany.
⁵ ClinSol GmbH & Co KG, Würzburg, Germany.
⁶ Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany. Electronic address: peter.fasching@uk-erlangen.de.
⁷ Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Germany.
⁸ Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany.
⁹ Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany; Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Erlangen, Germany.
¹⁰ Frankfurt Center of Bone Health Frankfurt, Germany.
¹¹ Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.
¹² gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany.
¹³ Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
¹⁴ Marienhospital Bottrop, Bottrop, Germany.
¹⁵ Gynecology I (Gynecologic Oncology), Gynäkologisches Zentrum Bonn Friedensplatz, Bonn, Germany.
¹⁶ Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
¹⁷ Oncologianova GmbH, Recklinghausen, Germany.
¹⁸ Oncology Practice at Bethanien Hospital, Frankfurt, Germany.
¹⁹ National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
²⁰ Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
²¹ Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany.
²² National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Dresden University Hospital, Dresden, Germany.
²³ Department of Gynecology and Obstetrics, Breast Center, and CCC Munich, Munich University Hospital, Germany.
²⁴ Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.

PMID: 33413981
PMCID: PMC7878444
DOI: 10.1016/j.breast.2020.12.007

No abstract available

PubMed Disclaimer

Erratum for

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY. Schneeweiss A, et al. Breast. 2020 Dec;54:88-95. doi: 10.1016/j.breast.2020.08.011. Epub 2020 Aug 29. Breast. 2020. PMID: 32956934 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Affiliations

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Other Literature Sources

Miscellaneous